A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
Phase of Trial: Phase III
Latest Information Update: 07 Dec 2019
Price : $35 *
At a glance
- Drugs Clazakizumab (Primary)
- Indications Renal transplant rejection
- Focus Registrational; Therapeutic Use
- Acronyms IMAGINE
- Sponsors Vitaeris
- 04 Sep 2019 Planned initiation date changed from 1 Jul 2019 to 1 Sep 2019.
- 31 Jul 2019 Planned initiation date changed from 1 Jun 2019 to 1 Jul 2019.
- 10 Jun 2019 Status changed from not yet recruiting to recruiting.